ALDX is a single-drug, March-2026 FDA coin-flip: approval unlocks AbbVie-led commercialization and $200M milestones; rejection risks a dilution-driven reset to cash value.
Overview
Aldeyra Therapeutics (ALDX) is a late-stage, pre-commercial biotech focused on first-in-class small molecules that modulate reactive aldehyde species (RASP)—upstream inflammatory mediators implicated in ocular and systemic disease. The investment centers on reproxalap, a topical ocular RASP modulator under FDA review for dry eye disease, with supportive data in allergic conjunctivitis. Aldeyra currently has no recurring product revenue and funds operations through cash reserves, financing tools, and partnership payments. The company’s strategy was reshaped by an AbbVie exclusive option agreement: if reproxalap is approved, AbbVie has a short window to opt into U.S. co-commercialization and ex-U.S. exclusivity, triggering significant non-dilutive cash inflows and long-term profit/royalty economics. Beyond reproxalap, Aldeyra is developing ADX-2191 for rare retinal diseases (Orphan/Fast Track) and next-generation systemic/retinal RASP modulators (ADX-248/ADX-246) for geographic atrophy and neuroinflammatory conditions. The overarching narrative is a potential transition from capital-consuming development to a partnered commercial royalty/profit-share model—highly contingent on a binary FDA outcome.